id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-3101-0022,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Guidance for Industry; Availability,Notice,Notice of Availability,2025-06-16T04:00:00Z,2025,6,2025-06-16T04:00:00Z,,2025-06-16T17:46:03Z,2025-10922,0,0,09000064b8e12d9a
FDA-2017-D-3101-0023,FDA,FDA-2017-D-3101,ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Guidance for Industry - Final Guidance,Other,Guidance,2025-06-16T04:00:00Z,2025,6,2025-06-16T04:00:00Z,,2025-06-16T18:00:16Z,,1,0,09000064b8e12f76
FDA-2017-D-3101-0018,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Draft Guidance for Industry; Availability,Other,Guidance,2022-12-05T05:00:00Z,2022,12,2022-12-05T05:00:00Z,2023-03-07T04:59:59Z,2025-06-16T18:00:48Z,,0,0,090000648551989c
FDA-2017-D-3101-0017,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-05T05:00:00Z,2022,12,2022-12-05T05:00:00Z,,2022-12-05T13:29:25Z,2022-26412,0,0,09000064855196fa
FDA-2017-D-3101-0011,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission of Facility  Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence); Draft Guidance for Industry;  Availability,Notice,Guidance,2017-11-06T05:00:00Z,2017,11,2017-11-06T05:00:00Z,2018-02-06T04:59:59Z,2017-11-06T14:47:02Z,2017-24099,0,0,0900006482c48219
FDA-2017-D-3101-0012,FDA,FDA-2017-D-3101,ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry,Other,Guidance,2017-11-06T04:00:00Z,2017,11,2017-11-06T04:00:00Z,2018-02-06T04:59:59Z,2025-06-16T18:01:07Z,,0,0,0900006482c4b344
FDA-2017-D-3101-0002,FDA,FDA-2017-D-3101,"ANDAs: Pre-Submission Facility Correspondence Associated with Priority
Submissions Guidance for Industry",Other,Guidance,2017-06-20T04:00:00Z,2017,6,2017-06-20T04:00:00Z,2017-09-19T03:59:59Z,2019-06-18T16:16:08Z,,0,0,09000064826f71e8
FDA-2017-D-3101-0001,FDA,FDA-2017-D-3101,"Abbreviated New Drug Applications: Pre-Submission Facility  Correspondence Associated with Priority Submissions; Draft Guidance
for Industry; Availability",Notice,Notice of Availability,2017-06-20T04:00:00Z,2017,6,2017-06-20T04:00:00Z,2017-09-19T03:59:59Z,2017-06-30T13:04:39Z,2017-12836,0,0,09000064826f5d6c